S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
Recruiting in Palo Alto (17 mi)
+39 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Southwest Oncology Group
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
RATIONALE: Chemotherapy plus interferon alfa may be effective for primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus interferon alfa in treating patients who have primary systemic amyloidosis.
Research Team
RA
Richard A. Larson, MD
Principal Investigator
University of Chicago
LF
Laura F. Hutchins, MD
Principal Investigator
University of Arkansas
Eligibility Criteria
Inclusion Criteria
Deposition of fibrillary protein with Congo red positive stain or characteristic electron microscopic appearance
Monoclonal light chain protein (Bence-Jones protein) in serum or urine or immunohistochemical studies
Evidence of tissue involvement other than carpal tunnel syndrome
See 7 more
Treatment Details
Interventions
- Dexamethasone (Corticosteroid)
- Interferon Alfa (Interferon)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: induction and maintenanceExperimental Treatment2 Interventions
dexamethasone induction followed by alpha interferon maintenance
Dexamethasone is already approved in Canada, Japan for the following indications:
Approved in Canada as Dexamethasone for:
- Inflammation
- Allergic reactions
- Respiratory diseases
- Skin conditions
- Eye diseases
Approved in Japan as Dexamethasone for:
- Inflammatory conditions
- Allergic states
- Respiratory diseases
- Blood disorders
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Norris Cotton Cancer CenterLebanon, NH
CCOP - Southeast Cancer Control ConsortiumWinston-Salem, NC
Arthur G. James Cancer Hospital - Ohio State UniversityColumbus, OH
MBCCOP - Massey Cancer CenterRichmond, VA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Southwest Oncology Group
Lead Sponsor
Trials
389
Patients Recruited
260,000+
SWOG Cancer Research Network
Lead Sponsor
Trials
403
Patients Recruited
267,000+
National Cancer Institute (NCI)
Collaborator
Trials
14080
Patients Recruited
41,180,000+
Cancer and Leukemia Group B
Collaborator
Trials
81
Patients Recruited
118,000+